OTC · CIK 0000880242
BLGO BIOLARGO, INC.
Insider trading from SEC Form 4. Last filing 11 d ago.
BIOLARGO, INC. (BLGO) has 43 SEC Form 4 filings on file from 7 insiders, the latest filed on Oct 2, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
7
with a Form 4 at this company
Signals
Open-market buys and sells at BIOLARGO, INC., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The newest 50 of 53 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Kenneth Reay Code Chief Science Officer | AGrant or award Common Stock | +566,261 | $0.08 | $45k | 26,974,580 | 11 d ago |
| Sep 30, 2026 | Jack B. Strommen director | AGrant or award Option to Purchase Common Stockderivative | +187,500 | - | - | 2,771,762 | 11 d ago |
| Sep 30, 2026 | Dennis E Marshall director | AGrant or award Option to Purchase Common Stockderivative | +281,248 | - | - | 6,056,317 | 11 d ago |
| Sep 30, 2026 | Christina Elaine Bray director | AGrant or award Option to Purchase Common Stockderivative | +234,375 | - | - | 1,781,075 | 11 d ago |
| Sep 30, 2026 | Linda Park director | AGrant or award Option to Purchase Common Stockderivative | +234,375 | - | - | 1,781,075 | 11 d ago |
| Sep 30, 2026 | Dennis P Calvert President | AGrant or award Common Stock | +931,886 | $0.08 | $75k | 11,989,994 | 11 d ago |
| Sep 30, 2026 | Kenneth Reay Code Chief Science Officer | GGift Common Stock | -2,000,000 | $0.00 | $0 | 24,974,580 | 11 d ago |
| Sep 30, 2026 | Dennis E Marshall director | AGrant or award Option to Purchase Common Stockderivative | +234,375 | - | - | 6,290,692 | 11 d ago |
| Sep 30, 2026 | Dennis P Calvert President | GGift Common Stock | +2,000,000 | $0.00 | $0 | 13,989,994 | 11 d ago |
| Jul 7, 2026 | Kenneth Reay Code Chief Science Officer | AGrant or award Common Stock | +532,567 | $0.11 | $60k | 26,408,319 | Jul 7, 2026 |
| Jun 30, 2026 | Jack B. Strommen director | AGrant or award Option to Purchase Common Stockderivative | +132,159 | - | - | 2,584,262 | Jul 2, 2026 |
| Jun 30, 2026 | Dennis P Calvert President | AGrant or award Common Stock | +699,569 | $0.11 | $79k | 10,838,194 | Jul 2, 2026 |
| Jun 30, 2026 | Dennis E Marshall director | AGrant or award Option to Purchase Common Stockderivative | +198,238 | - | - | 5,639,476 | Jul 2, 2026 |
| Jun 30, 2026 | Christina Elaine Bray director | AGrant or award Option to Purchase Common Stockderivative | +165,198 | - | - | 1,546,700 | Jul 2, 2026 |
| Jun 30, 2026 | Linda Park director | AGrant or award Option to Purchase Common Stockderivative | +165,198 | - | - | 1,546,700 | Jul 2, 2026 |
| Jul 1, 2026 | Dennis P Calvert President | AGrant or award Common Stock | +219,914 | $0.11 | $25k | 11,058,108 | Jul 2, 2026 |
| Jun 30, 2026 | Dennis E Marshall director | AGrant or award Option to Purchase Common Stockderivative | +115,741 | - | - | 5,804,674 | Jul 2, 2026 |
| Jun 22, 2026 | Dennis E Marshall director | AGrant or award Option to Purchase Common Stockderivative | +40,909 | - | - | 5,463,738 | Jun 24, 2026 |
| Mar 31, 2026 | Kenneth Reay Code Chief Science Officer | AGrant or award Common Stock | +69,444 | $0.16 | $11k | 25,875,752 | Apr 2, 2026 |
| Mar 31, 2026 | Dennis E Marshall director | AGrant or award Option to Purchase Common Stockderivative | +138,889 | - | - | 5,317,088 | Apr 1, 2026 |
| Mar 31, 2026 | Linda Park director | AGrant or award Option to Purchase Common Stockderivative | +115,741 | - | - | 1,381,502 | Apr 1, 2026 |
| Mar 31, 2026 | Christina Elaine Bray director | AGrant or award Option to Purchase Common Stockderivative | +115,741 | - | - | 1,381,502 | Apr 1, 2026 |
| Mar 31, 2026 | Jack B. Strommen director | AGrant or award Option to Purchase Common Stockderivative | +92,593 | - | - | 2,452,103 | Apr 1, 2026 |
| Mar 31, 2026 | Dennis E Marshall director | AGrant or award Option to Purchase Common Stockderivative | +115,741 | - | - | 5,432,829 | Apr 1, 2026 |
| Feb 1, 2026 | Charles K Dargan Chief Financial Officer | AGrant or award Option to Purchase Common Stockderivative | +300,000 | - | - | 5,931,668 | Feb 3, 2026 |
| Dec 31, 2025 | Kenneth Reay Code Chief Science Officer | AGrant or award Common Stock | +54,803 | $0.18 | $10k | 25,806,308 | Jan 5, 2026 |
| Dec 31, 2025 | Dennis E Marshall director | AGrant or award Option to Purchase Common Stockderivative | +122,084 | - | - | 5,144,645 | Jan 5, 2026 |
| Dec 31, 2025 | Jack B. Strommen director | AGrant or award Option to Purchase Common Stockderivative | +81,389 | - | - | 2,359,510 | Jan 5, 2026 |
| Dec 31, 2025 | Christina Elaine Bray director | AGrant or award Option to Purchase Common Stockderivative | +101,736 | - | - | 1,265,761 | Jan 5, 2026 |
| Dec 31, 2025 | Linda Park director | AGrant or award Option to Purchase Common Stockderivative | +101,736 | - | - | 1,265,761 | Jan 5, 2026 |
| Dec 31, 2025 | Dennis P Calvert President | AGrant or award Common Stock | +130,222 | $0.18 | $24k | 10,523,625 | Jan 5, 2026 |
| Dec 31, 2025 | Dennis E Marshall director | AGrant or award Option to Purchase Common Stockderivative | +101,736 | - | - | 5,246,381 | Jan 5, 2026 |
| Nov 14, 2025 | Dennis P Calvert President | AGrant or award Common Stock | +310,269 | $0.16 | $50k | 10,393,403 | Nov 17, 2025 |
| Nov 14, 2025 | Kenneth Reay Code Chief Science Officer | AGrant or award Common Stock | +313,754 | $0.16 | $50k | 25,751,505 | Nov 17, 2025 |
| Sep 30, 2025 | Dennis E Marshall director | AGrant or award Option to Purchase Common Stockderivative | +132,351 | - | - | 4,957,267 | Oct 2, 2025 |
| Sep 30, 2025 | Christina Elaine Bray director | AGrant or award Option to Purchase Common Stockderivative | +110,294 | - | - | 1,164,025 | Oct 2, 2025 |
| Sep 30, 2025 | Linda Park director | AGrant or award Option to Purchase Common Stockderivative | +110,294 | - | - | 1,164,025 | Oct 2, 2025 |
| Sep 30, 2025 | Jack B. Strommen director | AGrant or award Option to Purchase Common Stockderivative | +88,235 | - | - | 2,278,121 | Oct 2, 2025 |
| Sep 30, 2025 | Dennis E Marshall director | AGrant or award Option to Purchase Common Stockderivative | +110,294 | - | - | 5,067,561 | Oct 2, 2025 |
| Jul 14, 2025 | Kenneth Reay Code Chief Science Officer | AGrant or award Common Stock | +181,253 | $0.20 | $36k | 25,131,495 | Jul 16, 2025 |
| Jul 14, 2025 | Dennis P Calvert President | AGrant or award Common Stock | +169,498 | $0.20 | $34k | 10,029,542 | Jul 16, 2025 |
| Jun 30, 2025 | Dennis E Marshall director | AGrant or award Option to Purchase Common Stockderivative | +19,000 | - | - | 4,717,566 | Jul 2, 2025 |
| Jun 30, 2025 | Christina Elaine Bray director | AGrant or award Option to Purchase Common Stockderivative | +93,750 | - | - | 1,053,731 | Jul 2, 2025 |
| Jun 30, 2025 | Jack B. Strommen director | AGrant or award Option to Purchase Common Stockderivative | +75,000 | - | - | 2,189,886 | Jul 2, 2025 |
| Jun 30, 2025 | Linda Park director | AGrant or award Option to Purchase Common Stockderivative | +93,750 | - | - | 1,053,731 | Jul 2, 2025 |
| Jun 30, 2025 | Dennis E Marshall director | AGrant or award Option to Purchase Common Stockderivative | +112,501 | - | - | 4,765,781 | Jul 2, 2025 |
| Jun 30, 2025 | Dennis E Marshall director | AGrant or award Option to Purchase Common Stockderivative | +93,750 | - | - | 4,859,531 | Jul 2, 2025 |
| Dec 31, 2024 | Linda Park director | AGrant or award Option to Purchase Common Stockderivative | +98,684 | - | - | 893,017 | Jan 3, 2025 |
| Dec 31, 2024 | Christina Elaine Bray director | AGrant or award Option to Purchase Common Stockderivative | +98,684 | - | - | 893,017 | Jan 3, 2025 |
| Dec 31, 2024 | Dennis E Marshall director | AGrant or award Option to Purchase Common Stockderivative | +98,684 | - | - | 4,624,625 | Jan 3, 2025 |
50 of 53 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Christina Elaine Braydirector
- Dennis P CalvertPresident
- Kenneth Reay CodeChief Science Officer
- Charles K DarganChief Financial Officer
- Dennis E Marshalldirector
- Linda Parkdirector
- Jack B. Strommendirector
Questions about BLGO
Answered from the filings on this page, as of the latest one.
Are insiders buying BLGO?
No. In the last 90 days no insider at BIOLARGO, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade BLGO on the open market?
No open-market trade has been scored at BIOLARGO, INC.. The latest Form 4 on file was filed on Oct 2, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at BIOLARGO, INC.?
7 people have filed a Form 4 at BIOLARGO, INC., among them Christina Elaine Bray (director), Dennis P Calvert (President), Kenneth Reay Code (Chief Science Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.